Brief: Biophytis To Present Development Of Phase 3 Treatment For Sarcopenia

Biophytis SA

28/06/2022 14:03

June 28 (Reuters) - Biophytis SA  ALBPS.PA :
    * ON MONDAY BIOPHYTIS PRESENTS THE DEVELOPMENT OF SARCONEOS
(BIO101) IN PHASE 3 FOR THE TREATMENT OF SARCOPENIA AT THE 15TH
SCWD INTERNATIONAL CONGRESS
    * CO INTENDS TO INITIATE PHASE 3 STUDY BEFORE THE END OF
2022 
    * SARCONEOS (BIO101) HAS THE POTENTIAL TO BE THE FIRST DRUG
CANDIDATE EVER MOVING INTO PHASE 3 IN SARCOPENIA
    * DURATION OF THIS STUDY IS ESTIMATED AT 36 MONTHS FROM THE
INCLUSION OF FIRST PATIENT EXPECTED AT THE END OF 2022
    * COINTENDS TO FILE FOR CLINICAL TRIAL APPLICATION (CTA) IN
Q4
2022, DEPENDING ON FINAL DISCUSSIONS WITH FDA AND EMA

Source text for Eikon:  ID:nEQ3BfMLma 
Further company coverage:  ALBPS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))